New investigational drugs with single-agent activity in multiple myeloma

A. M. Rajan, Shaji K Kumar

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

The treatment of multiple myeloma (MM) is rapidly evolving. In the United States, four drugs (panobinostat, ixazomib, daratumumab and elotuzumab) were approved for the treatment of MM in 2015. As a result of improved diagnosis and therapy, there has been a dramatic improvement in the outcome of MM in the last decade, probably more than any other malignancy. Numerous agents continue to be studied in preclinical models and in clinical trials, with many demonstrating clinical efficacy that appears promising enough to have a trajectory for regulatory approval. The purpose of this article is to summarize the current data and provide perspective on new investigational agents with promising single-agent activity in MM. The agents reviewed include Isatuximab, an anti-CD38 monoclonal antibody; marizomib, a new proteasome inhibitor; oprozomib, an oral proteasome inhibitor; filanesib (ARRY-520), a kinesin spindle protein inhibitor; dinaciclib, a cyclin-dependent kinase inhibitor; venetoclax (ABT-199), a selective BCL-2 inhibitor; and LGH-447, pan PIM kinase inhibitor.

Original languageEnglish (US)
Pages (from-to)e451
JournalBlood Cancer Journal
Volume6
Issue number7
DOIs
StatePublished - Jul 29 2016

Fingerprint

Investigational Drugs
Multiple Myeloma
Proteasome Inhibitors
Kinesin
Cyclin-Dependent Kinases
Phosphotransferases
Monoclonal Antibodies
Clinical Trials
Pharmaceutical Preparations
Neoplasms
Proteins
4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

New investigational drugs with single-agent activity in multiple myeloma. / Rajan, A. M.; Kumar, Shaji K.

In: Blood Cancer Journal, Vol. 6, No. 7, 29.07.2016, p. e451.

Research output: Contribution to journalReview article

@article{5b228f7b6b9c4fa186bd2d8c6e27810f,
title = "New investigational drugs with single-agent activity in multiple myeloma",
abstract = "The treatment of multiple myeloma (MM) is rapidly evolving. In the United States, four drugs (panobinostat, ixazomib, daratumumab and elotuzumab) were approved for the treatment of MM in 2015. As a result of improved diagnosis and therapy, there has been a dramatic improvement in the outcome of MM in the last decade, probably more than any other malignancy. Numerous agents continue to be studied in preclinical models and in clinical trials, with many demonstrating clinical efficacy that appears promising enough to have a trajectory for regulatory approval. The purpose of this article is to summarize the current data and provide perspective on new investigational agents with promising single-agent activity in MM. The agents reviewed include Isatuximab, an anti-CD38 monoclonal antibody; marizomib, a new proteasome inhibitor; oprozomib, an oral proteasome inhibitor; filanesib (ARRY-520), a kinesin spindle protein inhibitor; dinaciclib, a cyclin-dependent kinase inhibitor; venetoclax (ABT-199), a selective BCL-2 inhibitor; and LGH-447, pan PIM kinase inhibitor.",
author = "Rajan, {A. M.} and Kumar, {Shaji K}",
year = "2016",
month = "7",
day = "29",
doi = "10.1038/bcj.2016.53",
language = "English (US)",
volume = "6",
pages = "e451",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - New investigational drugs with single-agent activity in multiple myeloma

AU - Rajan, A. M.

AU - Kumar, Shaji K

PY - 2016/7/29

Y1 - 2016/7/29

N2 - The treatment of multiple myeloma (MM) is rapidly evolving. In the United States, four drugs (panobinostat, ixazomib, daratumumab and elotuzumab) were approved for the treatment of MM in 2015. As a result of improved diagnosis and therapy, there has been a dramatic improvement in the outcome of MM in the last decade, probably more than any other malignancy. Numerous agents continue to be studied in preclinical models and in clinical trials, with many demonstrating clinical efficacy that appears promising enough to have a trajectory for regulatory approval. The purpose of this article is to summarize the current data and provide perspective on new investigational agents with promising single-agent activity in MM. The agents reviewed include Isatuximab, an anti-CD38 monoclonal antibody; marizomib, a new proteasome inhibitor; oprozomib, an oral proteasome inhibitor; filanesib (ARRY-520), a kinesin spindle protein inhibitor; dinaciclib, a cyclin-dependent kinase inhibitor; venetoclax (ABT-199), a selective BCL-2 inhibitor; and LGH-447, pan PIM kinase inhibitor.

AB - The treatment of multiple myeloma (MM) is rapidly evolving. In the United States, four drugs (panobinostat, ixazomib, daratumumab and elotuzumab) were approved for the treatment of MM in 2015. As a result of improved diagnosis and therapy, there has been a dramatic improvement in the outcome of MM in the last decade, probably more than any other malignancy. Numerous agents continue to be studied in preclinical models and in clinical trials, with many demonstrating clinical efficacy that appears promising enough to have a trajectory for regulatory approval. The purpose of this article is to summarize the current data and provide perspective on new investigational agents with promising single-agent activity in MM. The agents reviewed include Isatuximab, an anti-CD38 monoclonal antibody; marizomib, a new proteasome inhibitor; oprozomib, an oral proteasome inhibitor; filanesib (ARRY-520), a kinesin spindle protein inhibitor; dinaciclib, a cyclin-dependent kinase inhibitor; venetoclax (ABT-199), a selective BCL-2 inhibitor; and LGH-447, pan PIM kinase inhibitor.

UR - http://www.scopus.com/inward/record.url?scp=85030831844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030831844&partnerID=8YFLogxK

U2 - 10.1038/bcj.2016.53

DO - 10.1038/bcj.2016.53

M3 - Review article

VL - 6

SP - e451

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 7

ER -